Effect of Percutaneous Electrical Acupoint Stimulation on the Improvement of Incidence of
The goal of this study is to investigate the effect of combined acupoint electrical stimulation at Taiyuan (LU9) and Hegu (LI4) on improving the incidence of respiratory adverse events after extubation in patients during the recovery period from general anesthesia. The main content of this study involves selecting pati
| Condition(s) | Extubation, Respiratory Depression, Acupuncture Points, Hypoxia |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | The goal of this study is to investigate the effect of combined acupoint electrical stimulation at Taiyuan (LU9) and Hegu (LI4) on improving the incidence of respiratory adverse events after extubation in patients during the recovery period from general anesthesia. The main content of this study involves selecting patients who have undergone general anesthesia and are admitted to the Post Anesthesia Care Unit (PACU), with an expected 236 participants. The researchers will randomly assign participants to either the TEAS group or the control group using a random number table. In the TEAS group, electrodes will be applied to the upper limbs at the Taiyuan and Hegu acupoints, without intravenous infusion, and connected to a stimulation device. The stimulation will use a frequency of 2/100 Hz w |
| Who can participate | Inclusion Criteria: * 1: Age \>18 years old. 2: ASA I-III 3: Patients undergoing elective general anesthesia surgery who are extubated upon arrival to the PACU Exclusion Criteria: * 1: Preoperative comorbidities include severe cardiovascular or respiratory diseases 2: Serious reflux aspiration during the perioperative period 3: Concurrent psychiatric disorders 4: Local skin infections or nerve damage at the upper limb Taiyuan and Hegu acupoints |
| Ages | 18 Years to 100 Years |
| Sex | All |
| Accepts healthy volunteers | Yes |
| Lead sponsor | Nanjing First Hospital, Nanjing Medical University |
| Locations | Nanjing, Jiangsu, China; Nanjing, Jiangsu, China |
| Start date | 2025-01-25 |
| NCT ID | NCT06772961 |
| Official listing | https://clinicaltrials.gov/study/NCT06772961 |